R. Kim
Molecular Biology · New England Journal of Medicine · 2006
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 24 citations into it
- Cancer Research — 14 citations into it
Whom R. Kim trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- N. Ferrara (in Cancer Research)
Who trusts R. Kim
- N. Ferrara (in Ophthalmology)
Papers from R. Kim's perspective
Ordered by how strongly the researchers R. Kim trusts endorse each paper. Same corpus, a different order for every researcher.
- Opinion: Angiogenesis: an organizing principle for drug discovery? (Nature reviews. Drug discovery)
- The present and future role of microfluidics in biomedical research (Nature)
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue (Nature Protocols)
- Innovation: Metabolomics: the apogee of the omics trilogy (Nature reviews. Molecular cell biology)
- Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)
- Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. (Annual Review of Cell and Developmental Biology)
- Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox‐1 homeobox transcription factor (EMBO Journal)
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. (Molecular Therapy)
- The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. (Developmental Biology)
- The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. (Clinical Chemistry)
Their papers
- DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006) — 877 citations
- ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006) — 690 citations
- Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (2006) — 3,445 citations
- Ranibizumab for neovascular age-related macular degeneration. (2006) — 2,821 citations